MicroTransponder is developing the SAINT™ System*, a wireless neurostimulation technology platform to treat neurological disease. The SAINT™ is a minimally invasive device that does not require implanted batteries or wires. It is significantly smaller than current neurostimulation devices. The initial therapeutic area for the SAINT™ will be treatment for chronic pain. However, the dynamic team of neuroscientists and medical device engineers at MicroTransponder is developing the SAINT™ for a pipeline of additional indications based on Vagus Nerve Stimulation, including stroke rehabilitation, tinnitus, and anxiety. MicroTransponder has a substantial neurostimulation focused R&D program which includes an initiative to use the SAINT™ to assist the delivery of chemotherapy treatments for glioblastoma and other cancer therapeutics.

 *Investigational Device, Not for Sale in the United States, limited by Federal law.

 

Latest News

05/24/10
MIT Technology Review
Taming Tinnitus with Electrical Stimulation--MicroTransponder presents at Neurotech Conference in Boston

02/24/10
MTI Press Release
MicroTransponder Raises $10 Million to Begin Clinical Trials of Wireless Neurostimulation for Chronic Pain and Obtain FDA Clearance

04/22/09
Congressional Video
CEO Will Rosellini testifies before U.S. House of Representatives concerning Neurotechnology